Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition that can be caused by genetic mutations or aging, and is characterized by accumulating heart damage that ultimately leads to symptoms of heart failure. In ATTR-CM,…
The most common signs of transthyretin amyloid cardiomyopathy (ATTR-CM) are those typically associated with heart failure, although problems in the nervous system or other tissues can also occur. ATTR-CM is a type of cardiac amyloidosis,…
A diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) is typically reached through a series of tests to identify signs of the disease and rule out related disorders. ATTR-CM is a type of heart amyloidosis, a group…
The treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) is a multidisciplinary effort involving interventions to slow disease progression and manage symptoms. ATTR-CM is a form of amyloidosis, where protein clumps, called amyloid deposits, accumulate in tissues.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a form of heart disease that’s typically caused by genetic mutations or aging. Determining the root cause of ATTR-CM can help guide treatment decisions, understand prognosis, and determine if family…
Latest News & Community Perspectives
Discussion
An artificial intelligence (AI)-derived algorithm analyzing data from a standard, noninvasive heart test may help doctors identify transthyretin amyloid cardiomyopathy (ATTR-CM) among people with heart failure and preserved ejection fraction (HFpEF), a study suggested.
Discussion
People carrying mutations known to cause hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) who are not yet showing symptoms may already have disease-associated toxic protein clumps in the heart, a study suggests. Greater heart abnormalities…
Discussion
Vyndamax (tafamidis) leads to rapid and sustained increases in blood levels of the transthyretin (TTR) protein in people with transthyretin amyloid cardiomyopathy (ATTR-CM), and larger increases after one month are linked to a…
Discussion
Oct. 26 is World Amyloidosis Day, and advocates around the world are joining together to shine a light on transthyretin amyloid cardiomyopathy (ATTR-CM) and other forms of amyloidosis. Amyloidosis refers to a group of…
Discussion
Most people with transthyretin amyloidosis (ATTR) in China have a hereditary form of the rare disease and experience symptoms of both ATTR with polyneuropathy (ATTR-PN) — marked by nerve problems and muscle weakness —…
Discussion
Attruby (acoramidis) was associated with better heart-related outcomes and a lower risk of hospitalization than Vyndamax (tafamidis) among people with transthyretin amyloid cardiomyopathy (ATTR-CM), according to a new analysis of U.S. electronic…
Discussion
Long-term therapy with Attruby (acoramidis) significantly slows the decline in heart failure-related health status — a patient-reported assessment of symptoms, physical function, and quality of life — in adults with transthyretin amyloid cardiomyopathy…
Discussion
Treatment with Vyndamax (tafamidis) improves certain features of the heart’s structure and function in adults with transthyretin amyloid cardiomyopathy (ATTR-CM), according to an analysis of 13 imaging studies that involved more than 1,000…
Discussion
Attruby (acoramidis) may be better than Vyndamax (tafamidis) at preserving heart health among people with transthyretin amyloid cardiomyopathy (ATTR-CM), according to a new analysis of health insurance data in the U.S. While…
Discussion
Women with transthyretin amyloid cardiomyopathy (ATTR-CM) showed different clinical characteristics than men with the condition in pooled data from two previous studies of patients treated with Vyndamax (tafamidis). Although women appeared more symptomatic…